TREM1 expression in the tumor-associated Mφ (TAMs) from primary and recurrent glioblastomas obtained from the Brain Immune glioblastoma Atlas portal confirms an increase in the TREM1-positive subsets of TAMs from 21.3% in the primary glioblastoma to 36.8% in the recurrent glioblastoma (Figure 1E). This evidence concerns the gene TREM1 and neoplasm.